EMAMI LTD.-$ Q1 FY27 Results

Emami's consolidated (primary basis) revenue rose 14.9% YoY to ₹1,039 Cr (+12.3% QoQ), but consolidated PAT fell 15.4% YoY to ₹138.9 Cr (-2.9% QoQ), missing our pre-result Street consensus (revenue ~₹1,055 Cr — roughly in line, -1.5%; EPS ~₹4.36 vs actual ₹3.15 — a clear miss). This is the first print to consolidate Axiom Ayurveda (from April 1) and IncNut Digital (60% stake, from June 1), so YoY comparisons are not fully like-for-like.

The PAT decline is driven by two distinct effects. First, genuine operating margin compression: OPM fell to 21.8% from 23.7% YoY (though it expanded from 20.2% QoQ), and NPM fell to 13.1% from 17.7% YoY, on higher advertisement/promotion spend (₹203 Cr vs ₹180 Cr YoY) and employee costs (₹136 Cr vs ₹119 Cr YoY), alongside finance costs more than doubling YoY to ₹5.6 Cr on acquisition funding (₹100 Cr first tranche for Axiom's remaining 73.5% stake; ₹321 Cr for IncNut's 60% stake). Second, a tax-line swing: PBT before exceptional items actually rose 4.2% YoY to ₹194.7 Cr, but tax expense jumped to ₹55.8 Cr from ₹22.5 Cr as MAT credit accounting flipped from a ₹10.4 Cr benefit a year ago to a ₹13.5 Cr utilisation charge this quarter — a ~₹23.8 Cr negative swing that alone accounts for most of the increase in tax outgo. Stripping this MAT-line effect out, adjusted PAT is roughly flat YoY (-1.0%) rather than -15.4% reported, though the underlying operating-margin compression is real and independent of the tax effect.

The stock went into the print at ₹394.8, down 5.3% over the past month of trading.

Management's prior (Q4 FY26) guidance flagged margin improvement via cost discipline and a 3% price hike, and double-digit summer-portfolio growth for FY27; this quarter's revenue growth is consistent with that confidence, but the YoY margin compression runs counter to the margin-improvement guidance — a miss on that specific commitment, at least for Q1. International business was guided to return to double-digit growth only from Q2 FY27, so its Q1 trajectory (not separately disclosed here) is not yet a test of that promise. Standalone (core Emami, ex-new subsidiaries) PAT was ₹182.2 Cr with EPS ₹4.17, and its PBT of ₹233.6 Cr grew against a stronger base — a cleaner read on the core business than the consolidated number, which is now diluted by two newly acquired, lower-margin/loss-making entities: IncNut's first stub period (June 1-30) contributed a ₹0.9 Cr net loss on ₹14.7 Cr revenue. No management press release commentary was available in the extracted materials to corroborate these drivers independently.

Strategic investments (growing 61%, targeting ₹750–800 Cr FY27) are real and diversify earnings, justifying a long-term optimistic lens. But Q1 core business grew only 6% despite macro tailwinds; PAT fell 15.4% YoY amid margin compression. Near-term recovery hinges on unproven pricing power and commodity deflation. International −12%, recovery speculative. Margin trajectory credible but timing uncertain.

Analysts (Kaustav, Kunal, Arnab) pressed hard on core business deceleration and margin sustainability. Management acknowledged but deferred specifics ('confident', 'should be relatively better') rather than quantifying acceleration. Q&A was candid on challenges but defensive on core growth outlook.

Score 7/10. Clear on strategic investments thesis and rationale for portfolio shift. Transparent on cost pressures (360 bps decomposed). Some evasion on core business growth acceleration ('expect better' vs quantified target). Met revenue guidance (₹1,039 Cr), quantified strategic investments roadmap. But PAT down 15.4% and core business at 6% — misses on profitability and core momentum prior guidance.

Q1 is traditionally EMAMI's weakest quarter. The summer portfolio (cooling, hydration-focused products) peaks in May; June sees seasonal decline as temperatures moderate. Q4 FY26 showed this plainly: consolidated revenue fell 4% to ₹925 Cr, but the core story was the summer headwind. Strip out the summer portfolio and domestic business grew 11%—a healthy trajectory. The Board will approve Q1 results on Aug 4; Street consensus expects revenue near ₹1,055 Cr and EPS around ₹4.36.

But Q1 FY27 is not a typical Q1. On June 1, EMAMI closed its 59.69% acquisition of IncNut Digital (owner of Vedix and SkinKraft), scaling to 60% by mid-June. This is the first quarter with IncNut consolidated into the P&L—a material (and forward-looking) addition. IncNut's strength in premium, tech-enabled skincare aligns with EMAMI's premiumisation and digital strategy. The company targets new-age brands to scale from ~6% of consolidated turnover today to 25% by FY30.

Q1 will test two things: (1) Can core EMAMI sustain the 11% ex-summer growth shown in Q4? If yes, the organic momentum is real and the seasonal drag is temporary. If not, macro or competitive headwinds may be tightening. (2) How does IncNut integrate into the consolidated P&L? The acquisition was ₹321 Cr at 60% stake (including performance earnouts over 24 months). Revenue contribution and integration costs are the watch-items. Vedix and SkinKraft are high-margin, digitally native brands with strong retention; if they scale in EMAMI's distribution, margins could expand. If integration costs spike or distribution assumptions miss, consensus will reprice.

Ownership trends matter. FII holding fell from 11.89% (Q1 FY26) to 8.58% (Q4 FY26), a 331 bp decline over the year. This reflects broader India equity outflows, not EMAMI-specific weakness, but the Street is watching whether FII stabilises post-result or continues to fade. DII is steady (~26.9%); promoter fixed at 54.84%. No major share pledges or surprises in recent disclosures—Diwakar Finvest activity in Jun-Jul was routine pledge management within promoter group.